Diagnosing familial combined hyperlipidemia.
SoRelle
Ruth
R
D001055:Apolipoproteins B / Q000097:blood; D002309:Cardiology; D000075202:Contraindications; D004348:Drug Labeling; D004351:Drug Resistance / Q000235:genetics; D005062:European Union; D005260:Female; D005464:Fluorobenzenes / Q000009:adverse effects; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000235:genetics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D006950:Hyperlipidemia, Familial Combined / Q000175:diagnosis; D007333:Insulin Resistance; D015187:Lipectomy; D009765:Obesity / Q000378:metabolism / Q000601:surgery; D011743:Pyrimidines / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000139:chemically induced; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D001055:Apolipoproteins B; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D006903:Hydroxymethylglutaryl CoA Reductases